Clinical Trial Update: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing blinatumomab to standard chemotherapy in relapsed or refractory B-precursor acute lymphoblastic leukemia; the study was terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2017-08-09